Testosterone and Cardiovascular Risk — Key Points (Last-Minute Review)

Background

  • Testosterone deficiency (TD): a clinical syndrome with signs/symptoms plus low serum testosterone. Symptoms include reduced libido, erectile dysfunction, fatigue, depressed mood; signs include anemia, low bone density, increased fat mass.
  • Goal of testosterone therapy (T therapy): restore concentrations to the physiologic range to alleviate symptoms and improve body composition, mood, energy, and metabolic parameters.
  • Biochemical thresholds:
    • Low total testosterone (TT): typically TT < 300\ \text{ng/dL}\approx 10.4\ \text{nmol/L} or sometimes <400\ \text{ng/dL} depending on guidelines.
    • Bioavailable/free fractions may better reflect androgen status when SHBG is high, which increases with age. Common clinical ranges: free testosterone (FT) roughly 0.8–1.5 ng/dL0.8\text{–}1.5\ \text{ng/dL} (calculated) or 27–52 pmol/L27\text{–}52\ \text{pmol/L}.
  • Prevalence and treatment trends: TD is relatively common in middle-aged/older men; rising T prescriptions over the past decade, with concerns about marketing and overtreatment. Endocrine Society guidelines emphasize careful candidate selection and monitoring.
  • Level of evidence (LOE) framework used in reviews: IIa, Ib, Ia, NA as appropriate in context of outcomes (see summary in Table 10 of the source).

Controversy and key turning points

  • Late 2013–early 2014: two studies suggested increased cardiovascular (CV) risk with T prescriptions, triggering wide media coverage and regulatory interest (FDA review).
  • Critics note major methodological flaws in the controversial studies; subsequent reviews question the validity of claimed CV risks.
  • Overall message from comprehensive reviews: no convincing evidence that testosterone therapy increases CV risk; rather, observational data often show either neutral or beneficial associations with CV health when TD is corrected.

Major findings at a glance

  • Low endogenous T and CV risk: substantial literature shows inverse associations between T (TT, FT, bioavailable T) and mortality/CV risk; higher T generally linked with lower CV risk markers and mortality risk.
  • Testosterone therapy and CV risk factors: consistent evidence that T therapy reduces obesity and fat mass, waist circumference; improves glycemic control; modest favorable changes in lipid profile (small reductions in total cholesterol, LDL, HDL; triglycerides effect unclear).
  • Carotid atherosclerosis and IMT: multiple studies show inverse associations between T levels (TT, FT, bioavailable T) and carotid IMT or plaque burden; some trials show IMT reduction with TRT.
  • Exercise capacity and angina: in men with angina or heart failure, TRT can improve exercise tolerance and, in some studies, time-to-ischemia or functional measures.
  • Mortality signals with TRT in observational data: some observational cohorts report reduced mortality in men treated with T vs untreated controls; results are not from randomized trials and may reflect selection bias or confounding.

Studies and what they imply (crucial nuances)

  • Vigen et al., JAMA 2013 (retrospective): reported higher overall CV events with T prescription, but data handling (stabilized inverse propensity weighting) and data reporting issues undermined credibility; later corrections and calls for retraction emerged. FDA commentary highlighted limitations.
  • Finkle et al., PLoS One 2014 (retrospective): reported higher nonfatal MI after T prescription, but lacked a control group, short exposure windows, and had confounding limitations; FDA likewise warned about attributing risk to testosterone alone.
  • Basaria et al., NEJM 2010 (prospective): randomized, but in a frail elderly population with higher cardiovascular event reporting; events were not primary endpoints and the study design limits definitive conclusions about CV risk; later analyses suggested dose-related relationships but not conclusive evidence.
  • Xu et al., BMC Medicine 2013 (meta-analysis): suggested increased CV events with T therapy, but included studies with questionable events and relied heavily on a few influential trials; broader meta-analyses later contradicted this.
  • Corona et al., Expert Opinion on Drug Safety 2014 (meta-analysis of 75 trials): overall no evidence of increased CV risk with TRT; some subgroups (metabolic disease) showed favorable CV risk profiles. LoE: IIa for many CV risk factors and IIa for IMT/atherosclerosis endpoints; Ia for HbA1c/insulin resistance in diabetic cohorts in other syntheses.

Therapeutic effects on CV risk factors (essential points)

  • Body composition and obesity
    • TRT reduces fat mass and waist circumference; increases lean mass. LOE: Ib.
  • Glycemic control and insulin resistance
    • Improvements in HbA1c, fasting glucose, and insulin sensitivity in diabetic/prediabetic men; several analyses report HbA1c reductions around ~0.5–1.0% depending on study. LOE: Ia for HbA1c; IIa for insulin resistance measures.
  • Lipids
    • Small reductions in total cholesterol, LDL, and HDL; triglycerides show inconsistent or no clear improvement. LOE: IIa.
  • Inflammation
    • Mixed results; some trials show reductions in CRP/TNF-α; others show no consistent change. LOE: Ib.
  • Carotid IMT and atherosclerosis
    • Consistently inverse relationship between T levels (TT/FT/ bioavailable) and IMT or plaque burden; TRT associated with IMT improvements in some RCTs. LOE: IIa.
  • Angina and heart failure
    • In men with angina, TRT increased time to ischemia in several trials; in CHF, TRT improved exercise capacity and hemodynamic markers in some analyses. LOE: Ib for angina, Ia for CHF functional measures.

Mortality and cardiovascular outcomes in context

  • Observational mortality studies with TD and TRT show mixed but often favorable signals (e.g., Shores 2012; Muraleedharan 2013) suggesting reduced mortality with therapy in some populations; LOE IIa.
  • Randomized trials and meta-analyses focused on CV events generally do not show a clear increased risk with TRT when applied within physiologic ranges and appropriate patient selection; Corona 2014 (75-study meta-analysis) finds no CV risk signal; Basaria/FDA-era critiques remain important for understanding study limitations.
  • Net interpretation: current evidence does not support the claim that TRT increases CV risk; potential CV health benefits exist via improvements in body composition, insulin sensitivity, lipid profiles, and vascular markers in TD men. LOE IIa–Ia across various endpoints.

Practical takeaways for practice and exam recall

  • The controversy largely reflects study design limitations rather than clear biologic signals that TRT harms CV health. The weight of evidence supports that maintaining normal T levels is associated with improved CV risk factors and potential mortality benefits in TD men.
  • Key thresholds to remember:
    • TD suspected when TT is below 300 ng/dL≈10.4 nmol/L300\ \text{ng/dL} \approx 10.4\ \text{nmol/L}, with FT/bioavailable T often guiding treatment decisions.
  • TRT effects to recall (high-yield):
    • Fat mass ↓, lean mass ↑, waist circumference ↓ (LOE Ib).
    • HbA1c and insulin resistance improve in diabetics/prediabetics (HbA1c improvement shown in meta-analytic syntheses; LOE Ia).
    • Small favorable changes in TC/LDL/HDL; triglycerides not clearly affected (LOE IIa).
    • IMT and carotid atherosclerosis markers improve with TRT (LOE IIa).
    • TRT can improve exercise capacity in CHF and time to ischemia in angina (LOE Ia for CHF, Ib for angina).
  • For exam purposes: remember the key critique points about Vigen, Finkle, Basaria, and Xu, and the overarching consensus from major meta-analyses (Corona 2014) that TRT does not increase CV risk and may improve CV risk factors in TD men.

Conclusion (summary statement)

  • In the absence of long, large, placebo-controlled trials with CV outcomes, definitive statements about absolute CV risk of TRT are not possible. However, the accumulated literature supports a strong, favorable association between normal testosterone levels (endogenous or via therapy) and CV health, with TRT improving several CV risk factors and, in observational data, sometimes associated with reduced mortality. The public health risk lies in under-recognition and undertreatment of TD, not in proven CV harm from appropriate TRT.